Original Article

Rural–urban differences in antibiotic prescribing for uncomplicated urinary tract infection

Abbye W. Clark MD1, Michael J. Durkin MD, MPH2, Margaret A. Olsen PhD, MPH2,3, Matthew Keller MS2, Yinjiao Ma MS, MPH2, Caroline A. O’Neil MA, MPH2 and Anne M. Butler PhD2,3

1Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, 2Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri and 3Division of Public Health Sciences, Washington University School of Medicine, St Louis, Missouri

Abstract

Objective: To examine rural–urban differences in temporal trends and risk of inappropriate antibiotic use by agent and duration among women with uncomplicated urinary tract infection (UTI).

Design: Observational cohort study.

Methods: Using the IBM MarketScan Commercial Database (2010–2015), we identified US commercially insured women aged 18–44 years coded for uncomplicated UTI and prescribed an oral antibiotic agent. We classified antibiotic agents and durations as appropriate versus inappropriate based on clinical guidelines. Rural–urban status was defined by residence in a metropolitan statistical area. We used modified Poisson regression to determine the association between rural–urban status and inappropriate antibiotic receipt, accounting for patient- and provider-level characteristics. We used multivariable logistic regression to estimate trends in antibiotic use by rural–urban status.

Results: Of 670,450 women with uncomplicated UTI, a large proportion received antibiotic prescriptions for inappropriate agents (46.7%) or durations (76.1%). Compared to urban women, rural women were more likely to receive prescriptions with inappropriately long durations (adjusted risk ratio 1.10, 95% CI, 1.10–1.10), which was consistent across subgroups. From 2011 to 2015, there was slight decline in the quarterly proportion of patients who received inappropriate agents (48.5% to 43.7%) and durations (78.3% to 73.4%). Rural–urban differences varied over time by agent (duration outcome only), geographic region, and provider specialty.

Conclusions: Inappropriate antibiotic prescribing is quite common for the treatment of uncomplicated UTI. Rural women are more likely to receive inappropriately long antibiotic durations. Antimicrobial stewardship interventions are needed to improve outpatient UTI antibiotic prescribing and to reduce unnecessary exposure to antibiotics, particularly in rural settings.

(Received 3 December 2020; accepted 14 January 2021; electronically published 24 February 2021)

Appropriate antibiotic prescribing is an important clinical and public health goal because inappropriate antibiotic use is associated with increased risk of treatment failure, adverse events, antibiotic resistance, and healthcare costs. Uncomplicated urinary tract infections (UTIs) account for ~10.5 million ambulatory visits annually in the United States, and they are a common reason for outpatient antibiotic use in otherwise healthy females. The international clinical practice guidelines for treatment of uncomplicated UTI in women, updated in 2010 by the Infectious Diseases Society of America (IDSA) and the European Society for Microbiology and Infectious Diseases, recommend several first-line antibiotic agents and durations based on efficacy results from randomized clinical trials and known prevalence of antibiotic resistance. Guidelines recommend empiric use of nitrofurantoin or trimethoprim-sulfamethoxazole (TMP-SMX) as first-line agents, reserving fluoroquinolones for infections other than uncomplicated UTIs because of the risk of rising antibiotic resistance and serious adverse events generally outweighs the benefits. However, most antibiotic prescriptions for uncomplicated UTIs are suboptimal because they are written for nonrecommended agents and durations.

Given the high burden of inappropriate antibiotic prescribing among women with uncomplicated UTIs in the United States, research on contemporary patterns of treatment is needed to identify disparities in appropriate antibiotic use. Knowledge about current practice patterns is needed to inform antimicrobial stewardship programs, which could ultimately enhance outpatient antibiotic prescribing and improve health outcomes. It is important to identify settings characterized by higher inappropriate antibiotic prescribing; such settings could be targets for interventions designed to improve guideline adherence.

The rural health disparity has been a recent focus in the United States, and its improvement is a priority of the Department of Health and Human Services. Previous studies on respiratory tract and pediatric infections have identified associations between

Author for correspondence: Anne M. Butler, E-mail: anne.butler@wustl.edu

PREVIOUS PRESENTATION: Preliminary findings were presented at the 2020 American College of Physicians Missouri Chapter annual meeting October 9–29 and ID Week 2020 October 22–25.

Cite this article: Clark AW, et al. (2021). Rural–urban differences in antibiotic prescribing for uncomplicated urinary tract infection. Infection Control & Hospital Epidemiology, 42: 1437–1444, https://doi.org/10.1017/ice.2021.21

© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.

Downloaded from https://www.cambridge.org/core, 22 Apr 2022 at 16:55:35, subject to the Cambridge Core terms of use.
inappropriate antibiotic prescribing and individual- and provider-level factors, including geographic region, rural–urban status, and provider specialty.\textsuperscript{14,15} However, no large-scale studies have evaluated rural–urban differences in inappropriate outpatient antibiotic prescribing for UTIs.\textsuperscript{16}

To address this knowledge gap, we analyzed rural–urban differences in real-world antibiotic treatment patterns for the outpatient treatment of uncomplicated UTIs in a large cohort of US commercially insured, premenopausal women. We explored rural–urban differences in temporal trends and risk of inappropriate antibiotic use by agent and duration, both overall and within subgroups, comparing to current IDSA guidelines to determine prescription appropriateness.

\section*{Methods}

\subsection*{Data source}

The IBM MarketScan commercial database (2006–2015) includes healthcare data for millions of commercially insured individuals from all 50 US states and the District of Columbia. The database includes deidentified longitudinal paid physician, pharmacy, and hospital claims data linked to demographic information from large employers and health plans that insure employees, their spouses, and dependents.\textsuperscript{17} These data have been used widely in health services and pharmacoepidemiologic research due to their large quantity, national representation, longitudinal structure, and comprehensive capture of outpatient services, inpatient services, and outpatient drug claims. Drug information represents prescriptions filled at a pharmacy. Our study using deidentified data was considered exempt from human subject review by the Institutional Review Board at Washington University.

\subsection*{Study design and population}

We constructed a cohort of women diagnosed and treated for uncomplicated UTI, defined in accordance with criteria outlined in current guidelines, using methods previously described.\textsuperscript{8,9} The cohort included premenopausal women aged 18–44 years who received an outpatient diagnosis of uncomplicated UTI (ICD-9-CM diagnosis codes 595.0, 595.9, or 599.0) with an accompanying antibiotic prescription from April 1, 2011, to June 30, 2015. The index date was defined as the date of a filled oral prescription for an antibiotic with activity against common uropathogens, which occurred on the day of or after the diagnosis of uncomplicated UTI. The 180-day baseline period prior to the index date was used to identify exclusion criteria and covariates. To ensure adequate ascertainment of medical history, women without continuous enrollment in a medical plan or prescription drug coverage during the 180-day baseline period were excluded. To meet the definition of uncomplicated UTI,\textsuperscript{8} women were excluded if they received diagnoses or prescription medications during the 180-day baseline period for pregnancy, urinary comorbidities or abnormalities, pyelonephritis, diabetes, systemic autoimmune conditions, spinal cord injuries, or hematologic or solid-organ malignancies (Supplementary Tables 1–3 online). To restrict the study population to women with community-acquired UTIs, women were excluded if they had been hospitalized within 90 days prior to the index date. To restrict the study population to new users of antibiotics, women were excluded if they had received an antibiotic in the 30 days prior to the index date or if they had an infection in the 30 days prior to or on the index date (Supplementary Table 4 online).

\begin{table}[h]
\centering
\caption{Guideline-Recommended Antibiotic Therapy for Acute Uncomplicated Cystitis by Antibiotic Agent and Duration\textsuperscript{a}}
\begin{tabular}{|c|c|}
\hline
\textbf{Antibiotic agent} & \textbf{Recommended Duration} \\
\hline
\textbf{First-line regimen} & \\
Nitrofurantoin & 5 days \\
Trimethoprim-sulfamethoxazole & 3 days \\
Fosfomycin trometamol & 1 day \\
\hline
\textbf{Non–first-line regimen} & \\
Fluoroquinolones & 3 days \\
\β-Lactams & 3–7 days \\
Trimethoprim monotherapy & 3 days \\
\hline
\end{tabular}
\textsuperscript{aAdapted from the 2011 IDSA clinical practice guidelines for the treatment of acute uncomplicated cystitis in women.\textsuperscript{9}}
\end{table}

\subsection*{Rural–Urban definition}

We classified individuals as urban if the primary beneficiary resided in a metropolitan statistical area; otherwise, the individual was classified as rural. IBM mapped the 5-digit postal zip code of each primary beneficiary’s residence according to the US Census Bureau geographical mapping classification, which requires each metropolitan statistical area to have at least 1 urbanized area of \textgreek{ge}50,000 inhabitants and includes their nearby communities if they are socioeconomically joined together.\textsuperscript{17,18}

\subsection*{Antibiotic outcome definitions}

Table 1 presents the IDSA guideline-recommended first-line and non–first-line antibiotic agents as well as the recommended duration for treatment of uncomplicated UTI.\textsuperscript{8} In accordance with these guidelines, we separately classified antibiotic prescriptions as appropriate or inappropriate based on antibiotic agent and duration, as described in our previous work.\textsuperscript{11} We classified first-line agents (nitrofurantoin, trimethoprim-sulfamethoxazole [TMP-SMX], and fosfomycin) as appropriate and non–first-line agents (fluoroquinolones and \β-lactams) as inappropriate. In accordance with current guidelines, and because TMP monotherapy use was rare, we considered TMP monotherapy to be equivalent to TMP-SMX. For individuals who received multiple UTI-related antibiotic prescriptions, we classified the prescription as appropriate if they received only 1 first-line agent and inappropriate if they received multiple first-line agents or only non–first-line agents (on the same date). We classified antibiotic prescriptions as appropriate duration when the duration matched the recommended duration per current guidelines (Table 1).\textsuperscript{8} Specifically, the following regimens were classified as appropriate duration: nitrofurantoin 5-day regimen, TMP-SMX (including TMP monotherapy) 3-day regimen, fosfomycin 1-day regimen, fluoroquinolones 3-day regimen, and \β-lactams 3–7-day regimens. All other regimens were classified as inappropriate duration. For individuals who received multiple UTI-related antibiotic prescriptions, we classified the duration as appropriate if each regimen was for the recommended duration; otherwise, we classified the duration as inappropriate if the regimen was not the recommended duration.

\subsection*{Covariate assessment}

Covariate information was collected during the 180-day baseline period on age, year, state, geographic region, provider type, health insurance plan type, receipt of urinalysis at index, receipt of urine
Table 2. Characteristics of the Study Population

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (N = 670,450)</th>
<th>Urban (N = 578,117)</th>
<th>Rural (N = 92,333)</th>
<th>Standardized Mean Differencea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median y (IQR)</td>
<td>30.0 (23.0–38.0)</td>
<td>30.0 (23.0–38.0)</td>
<td>30.0 (22.0–38.0)</td>
<td>0.01</td>
</tr>
<tr>
<td>Age group, y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18–24</td>
<td>215,624 (32.2)</td>
<td>184,517 (31.9)</td>
<td>31,107 (33.7)</td>
<td>0.07</td>
</tr>
<tr>
<td>25–29</td>
<td>103,181 (15.4)</td>
<td>90,633 (15.7)</td>
<td>12,548 (13.6)</td>
<td></td>
</tr>
<tr>
<td>30–34</td>
<td>108,616 (16.2)</td>
<td>94,040 (16.3)</td>
<td>14,576 (15.8)</td>
<td></td>
</tr>
<tr>
<td>35–39</td>
<td>116,458 (17.4)</td>
<td>100,164 (17.3)</td>
<td>16,294 (17.6)</td>
<td></td>
</tr>
<tr>
<td>40–44</td>
<td>126,571 (18.9)</td>
<td>108,763 (18.8)</td>
<td>17,808 (19.3)</td>
<td></td>
</tr>
<tr>
<td>Year</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>150,138 (22.4)</td>
<td>128,083 (22.2)</td>
<td>22,055 (23.9)</td>
<td>0.07</td>
</tr>
<tr>
<td>2012</td>
<td>179,757 (26.8)</td>
<td>153,963 (26.6)</td>
<td>25,794 (27.9)</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>141,138 (21.1)</td>
<td>122,451 (21.2)</td>
<td>18,687 (20.2)</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>147,823 (22.0)</td>
<td>128,647 (22.3)</td>
<td>19,176 (20.8)</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>51,594 (7.7)</td>
<td>44,973 (7.8)</td>
<td>6,621 (7.2)</td>
<td></td>
</tr>
<tr>
<td>Region of residence</td>
<td></td>
<td></td>
<td></td>
<td>0.39</td>
</tr>
<tr>
<td>Northeast</td>
<td>103,752 (15.5)</td>
<td>94,007 (16.3)</td>
<td>9,745 (10.6)</td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>147,362 (22.0)</td>
<td>123,285 (21.3)</td>
<td>24,077 (26.1)</td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>280,343 (41.8)</td>
<td>232,172 (40.2)</td>
<td>48,171 (52.2)</td>
<td></td>
</tr>
<tr>
<td>West</td>
<td>138,993 (20.7)</td>
<td>128,653 (22.3)</td>
<td>10,340 (11.2)</td>
<td></td>
</tr>
<tr>
<td>Provider type</td>
<td></td>
<td></td>
<td></td>
<td>0.33</td>
</tr>
<tr>
<td>Emergency medicine</td>
<td>56,573 (8.4)</td>
<td>48,621 (8.4)</td>
<td>7,952 (8.6)</td>
<td></td>
</tr>
<tr>
<td>Internal medicine</td>
<td>92,589 (13.8)</td>
<td>83,268 (14.4)</td>
<td>9,321 (10.1)</td>
<td></td>
</tr>
<tr>
<td>Family medicine &amp; pediatrics NEC</td>
<td>239,628 (35.7)</td>
<td>202,039 (34.9)</td>
<td>37,589 (40.7)</td>
<td></td>
</tr>
<tr>
<td>OBGYN</td>
<td>41,014 (6.1)</td>
<td>37,057 (6.4)</td>
<td>3,957 (4.3)</td>
<td></td>
</tr>
<tr>
<td>MD/DD NEC</td>
<td>42,301 (6.3)</td>
<td>35,627 (6.2)</td>
<td>6,674 (7.2)</td>
<td></td>
</tr>
<tr>
<td>NP/PA</td>
<td>45,401 (6.8)</td>
<td>34,571 (6.0)</td>
<td>10,830 (11.7)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>133,545 (19.9)</td>
<td>119,774 (20.7)</td>
<td>13,771 (14.9)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>19,399 (2.9)</td>
<td>17,160 (3.0)</td>
<td>2,239 (2.4)</td>
<td></td>
</tr>
<tr>
<td>Receipt of urine tests at index</td>
<td></td>
<td></td>
<td></td>
<td>0.10</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>537,258 (80.1)</td>
<td>460,102 (79.6)</td>
<td>77,156 (83.6)</td>
<td></td>
</tr>
<tr>
<td>Culture</td>
<td>340,643 (50.8)</td>
<td>299,733 (51.8)</td>
<td>40,910 (44.3)</td>
<td></td>
</tr>
<tr>
<td>Health plan type</td>
<td></td>
<td></td>
<td></td>
<td>0.32</td>
</tr>
<tr>
<td>Basic, comprehensive or high-deductible</td>
<td>41,617 (6.2)</td>
<td>36,592 (6.3)</td>
<td>5,025 (5.4)</td>
<td></td>
</tr>
<tr>
<td>CDHP</td>
<td>50,967 (7.6)</td>
<td>43,924 (7.6)</td>
<td>7,043 (7.6)</td>
<td></td>
</tr>
<tr>
<td>EPO or PPO</td>
<td>416,495 (62.1)</td>
<td>351,874 (60.9)</td>
<td>64,621 (70.0)</td>
<td></td>
</tr>
<tr>
<td>HMO</td>
<td>87,588 (13.1)</td>
<td>82,962 (14.4)</td>
<td>4,626 (5.0)</td>
<td></td>
</tr>
<tr>
<td>POS or POS with capitation</td>
<td>46,669 (7.0)</td>
<td>40,354 (7.0)</td>
<td>6,315 (6.8)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>27,114 (4.0)</td>
<td>22,411 (3.9)</td>
<td>4,703 (5.1)</td>
<td></td>
</tr>
</tbody>
</table>

Note: CDHP, consumer-driven health plans; DO, doctor of osteopathic medicine; EPO, exclusive provider organization; HMO, health maintenance organization; IQR, interquartile range; MD, medical doctor; NEC, not elsewhere classified; NP, nurse practitioner; OBGYN, obstetrics and gynecology; PA, physician’s assistant; POS, point of service; PPO, Preferred provider organization. aStandardized mean differences <0.10 indicate balance in observed covariates between rural and urban women.

Statistical analysis

We summarized the distribution of antibiotic prescription agents and durations by rural–urban status. We plotted state-level maps of the proportion of antibiotic prescriptions with inappropriate agents or durations, stratified by rural–urban status. We calculated the standardized mean differences of baseline covariates to characterize imbalances of observed covariates. To examine the relationship between rural–urban status and inappropriate antibiotic receipt, we used modified Poisson regression to estimate risk ratios (RRs) and 95% confidence intervals (CIs), adjusting for age, year, geographic

culture at index, and type of outpatient encounter (in-person or laboratory only).

Infection Control & Hospital Epidemiology

Downloaded from https://www.cambridge.org/core. 22 Apr 2022 at 16:55:35, subject to the Cambridge Core terms of use.
region, provider type, receipt of urinalysis at index, and receipt of urine culture at index. We built a separate model for each outcome (ie, inappropriate agent and inappropriate duration). In sensitivity analyses, we also adjusted for health insurance plan type.

To describe temporal trends in inappropriate antibiotic use by calendar quarter, we used logistic regression models to generate adjusted estimates of the proportion of rural versus urban patients who received inappropriate antibiotic agents or durations. Calendar quarter was treated as a categorical variable in the models to relax the assumption of linearity. We plotted the adjusted estimates, which are population marginal means that account for changes over time in age, geographic region, receipt of urinalysis at UTI diagnosis, receipt of urine culture at UTI diagnosis, and provider specialty. Trend lines were calculated as a smoothed conditional mean of the quarterly adjusted estimates. We performed subgroup analyses by stratifying models by antibiotic agent (duration outcome only), geographic region, and provider type.

Results

Cohort characteristics

We identified 670,450 women who met study eligibility criteria from an original 1,349,276 women (Supplementary Fig. 1 online). Most women (86.2%) were from urban areas, and 13.8% were from rural areas. Table 2 presents characteristics of the study population stratified by rural–urban status. Rural and urban women had a similar median age (30 years). Compared to urban women, rural women were more likely to reside in the South (52.2% vs 40.2%) and the Midwest (26.1% vs 21.3%), and they were less likely to reside in the Northeast (10.6% vs. 16.3%) or the West (11.2% vs 22.3%). The distribution of provider type differed by rural–urban status. Compared to urban women, rural women were similarly likely to have been diagnosed with UTI by an emergency medicine physician, were less likely to have been diagnosed by internal medicine or obstetrics/gynecology (OBGYN) physicians, and were more likely to have been diagnosed by family medicine or pediatric physicians or nonphysicians. Patterns of urine testing at index date differed by rural–urban status because rural women were more likely than urban women to be tested with a urinalysis (83.6% vs 79.6%) but less likely to be tested with a urine culture (44.3% vs 51.8%).

Risk of receipt of inappropriate antibiotic agent

Figure 1 and Supplementary Table 5 (online) present the distribution of antibiotic prescriptions by agent, overall and by rural–urban status. The most commonly prescribed agents were fluoroquinolones and the first-line agents TMP-SMX and nitrofurantoin. A similar proportion of antibiotic prescriptions were inappropriate agents for rural (45.9%) and urban (46.9%) women, with similar percentages for individual agents. The use of inappropriate agents was similar between rural and urban women: fluoroquinolones (41.0% vs 41.7%), β-lactams (4.8% vs 5.0%), multiple agents without first-line agents (0.1%), and multiple agents with
The association between rural–urban status and inappropriate agent also varied across provider specialties (Supplementary Fig. 4 online). Compared to urban women, the risk of receipt of an inappropriate agent among rural women was higher for OB-GYN providers (adjusted RR 1.09, 95% CI, 1.04–1.14), was similar for emergency medicine providers, and was lower for internal medicine (adjusted RR 0.93, 95% CI, 0.91–0.95) and family medicine and pediatric providers (adjusted RR 0.96, 95% CI, 0.95–0.97).

Risk of receipt of inappropriate antibiotic duration

Figure 1 and Supplementary Table 6 (online) present the distribution of antibiotic prescriptions by duration, overall and by rural–urban status. Most prescriptions (76.1%) were written for inappropriate durations. Of 507,737 prescriptions with inappropriate duration, almost all were written for a duration that was longer (N = 501,496; 98.8%) than recommended, rather than shorter (N = 6,241; 1.2%). For all antibiotic agents combined, rural women were prescribed inappropriate antibiotic durations more frequently than urban women (83.9% vs 74.9%). Similarly, within analyses stratified by antibiotic agent, rural women received more prescriptions with inappropriate durations than urban women: nitrofurantoin (85.4% vs 80.7%), TMP-SMX (84.4% vs 70.4%), fluoroquinolones (87.1% vs 78.5%), and β-lactams (45.8% vs 37.4%).

Over the study period, the quarterly proportion of patients who received inappropriate durations declined from 78.3% in mid-2011 to 73.4% in mid-2015 (Fig. 2B). The use of inappropriate agents declined among urban women (from 77.1% to 72.0%) and less so among rural women (from 85.1% to 83.2%). State-level maps illustrate ubiquitous use of antibiotic prescriptions with inappropriate durations in all regions, particularly the South and Midwest (Fig. 4). Rural–urban differences in inappropriate duration use remained generally constant over time within subgroups of antibiotic agent, geographic region, and provider specialty (Supplementary Figs. 5–7 online).

In the multivariable model, rural women were 10% more likely to receive an antibiotic prescription for an inappropriate duration (adjusted RR 1.10, 95% CI, 1.10–1.10) compared to urban women (Table 3). Results were robust to additional adjustment for health insurance plan type. Results of subgroup analyses were consistent across geographic regions, provider specialties, and antibiotic agents (Supplementary Fig. 8 online).

Discussion

We conducted a cohort study using a large claims database to examine rural–urban differences in real-world antibiotic treatment patterns in a population of uncomplicated UTI patients with commercial insurance in the United States. Of 670,450 patients in our study, nearly half received inappropriate agents and almost three-quarters received prescriptions with inappropriately long treatment durations. We observed little rural–urban difference in the receipt of inappropriate agents in the overall population, but results varied across geographic regions, provider specialties, and calendar time. We observed rural–urban differences in receipt of antibiotic prescriptions for inappropriate durations, wherein rural women were more likely to receive inappropriately long durations. These differences in inappropriate duration were consistent across antibiotic agents, geographic regions, and provider specialties. Overall, we observed slight decline in inappropriate antibiotic use for UTI (both by agent and duration) over time.

Our observations of overall or subgroup variability in rural–urban differences in appropriate use of antibiotic agents and ≥2 first-line agents (0.1%). Rural women received more TMP-SMX (33.3% vs 26.4%) and less nitrofurantoin (20.8% vs 26.7%).

Over the study period, the proportion of patients that received inappropriate agents by quarter declined from 48.5% in mid-2011 to 43.7% in mid-2015 (Fig. 2A). The use of inappropriate agents declined slightly among both urban (from 48.8% to 43.5%) and rural women (from 46.6% to 44.8%). State-level maps illustrated that women were more likely to receive inappropriate agents in the South and West regions, irrespective of rural–urban status (Fig. 3). Subgroup analyses demonstrated that rural–urban differences in inappropriate agent use varied over time within geographic regions (e.g., Northeast and West) and provider specialties (e.g., internal medicine and OB-GYN) (Supplementary Figs. 2 and 3 online). For example, among internal medicine physicians, inappropriate agent use was higher in rural areas in 2011, was similar by 2013, and was higher again by 2015.

In the multivariable model, rural women had a slightly lower risk of receipt of an inappropriate antibiotic agent (adjusted RR, 0.98; 95% CI, 0.98–0.99) compared to urban women (Table 3). In the sensitivity analysis, results did not change appreciably in the model that also accounted for health insurance plan type. The association between rural–urban status and inappropriate agent varied across geographic regions (Supplementary Fig. 4 online). Compared to urban women, risk of receipt of an inappropriate agent among rural women was similar in the South and Midwest but was lower in the West (adjusted RR 0.92, 95% CI, 0.90–0.95) and the Northeast (adjusted RR 0.94, 95% CI, 0.92–0.97).
durations have several possible explanations. Regional variability in agent use may be related to local patterns of uropathogen resistance, especially for *Escherichia coli*, the predominant bacterial cause of UTIs. However, we are not aware of regional uropathogen resistance data in the United States with which to compare with our findings. It is recommended that first-line TMP-SMX be avoided in settings with known local resistance; first-line nitrofurantoin is an appropriate alternative choice due to minimal resistance, though studies of antibiotic prescriptions for other indications and patient populations demonstrate that providers frequently prescribe non–first-line agents.

In addition, rural–urban differences in use of appropriate antibiotic durations may be related to patient- and provider-level factors. For example, distance to healthcare (a patient-level factor) is associated with lower adherence to treatment and poorer outcomes in oncology patients. In the context of our study on antibiotic prescribing, rural women were more likely to receive longer treatment durations, possibly in an effort to avoid treatment failure-related healthcare encounters that require travel. These rural–urban differences may also be associated with provider-level factors. Late-career physicians, which are more prevalent in rural locations, are more likely to prescribe antibiotics with longer durations.

Our study has several potential limitations. First, our guideline-based definition of inappropriate duration may be too lenient given recent meta-analytic evidence that shorter-course regimens of some agents have similar effects on clinical response; however,
the impact of possible misclassification on the results would be minimal because the proportion of prescriptions with inappropriate durations were overwhelmingly longer (98.8%) rather than shorter (1.2%) than recommended. Second, the study population is limited to commercially insured women from a database that oversamples residents of the South and undersamples residents of the West. Thus the results may not be generalizable to other populations such as Medicaid-insured or uninsured women, and they may not be directly generalizable to the commercially insured population in the United States. Third, our definition of rural–urban status was based on zip-code–level data rather than distance to urbanized areas and clusters or access to healthcare.\(^4\) Individuals classified as rural residents in our study reside in a wide variety of settlements, from densely settled small towns and exurbs on the fringes of urban areas, to more sparsely populated and remote areas.\(^13\) Fourth, the database lacked information on race or ethnicity or income level; thus, we were not able to account for these important disparity-related variables in the analysis, which may result in confounding bias. Lastly, test results from urine cultures were not available in the database; therefore, we were not able to account for prescribing decisions influenced by susceptibility results. However, we expect the impact of test results on prescribing practices to be minimal because guidelines recommend empiric treatment of uncomplicated UTI.

Despite these limitations, our study identified rural–urban differences in antibiotic prescribing, including an actionable disparity in the duration of antibiotics that disproportionately affects women who live in rural locations. In recent years, little effective progress has been achieved to reduce inappropriate antibiotic prescribing for uncomplicated UTI. Given the large quantity of inappropriate prescriptions annually in the United States, as well as the negative patient- and society-level consequences of unnecessary exposure to antibiotics, antimicrobial stewardship interventions are needed to improve outpatient UTI antibiotic prescribing, particularly in rural settings. Existing recommendations for the promotion of outpatient antibiotic stewardship include establishing personal and policy commitment to change, reporting progress, and enhancing education around best practices.\(^32\) Future research is needed to effectively identify, disseminate, and implement guideline-concordant antibiotic prescribing in rural settings.

Financial support. This work was supported by a grant from the NCATS (NIH grant no. K23 TR002346 to A.M.B. and M.J.D.). Data programming for this study was conducted by the Center for Administrative Data Research, which is supported in part by the Washington University Institute of Clinical and Translational Sciences (grant no. U1 TR002345) from the National Center for Advancing Translational Sciences at the NIH (grant no. R24 HS19455) through the Agency for Healthcare Research and Quality.

Conflicts of interest. M.A.O. reported receiving investigator-initiated research funds from Sanofi Pasteur, Pfizer, and Merck and serving as a consultant for Pfizer.

Supplementary material. To view supplementary material for this article, please visit https://doi.org/10.1017/ice.2021.21

References


29. Fordyce MA, Doescher MP, Skillman SM. *The Aging of the Rural Primary Care Physician Workforce: Will Some Locations Be More Affected than Others?* Seattle, WA: WWAMI Rural Health Research Center, University of Washington School of Medicine, Department of Family Medicine; 2013.

